A minority of FH patients is identified and labeled as such, which impacts treatmentAug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
CSI Rome Kausik Ray (Londen, VK) was involved in a project which investigated in UK databases which proportion of the predicted population with FH has been identified and is labelled as such. Johanneke van den Berg and Corien Flint (both Utrecht) discuss the consequences of underdetection with him, and how this may be improved.
- How well is FH identified and coded in databases in the UK? 0:32
- Do newly identified FH patients adequately ininitate and continue statin treatment? 2:36
- Statin levels depend on whether a patient is labelled as FH or not 3:19
- Missed opportunities to manage CV risk in FH patients 3:51
- An FH diagnosis should be followed by cascade screening 6:37
- More awareness is needed among physicians about diagnosis, treatment, follow-up, referral and cascade screening 8:33
In the Cardiovascular Scene Investigation (CSI) series, young clinicians with an investigative mindset interview experts about the context and meaning of the results they just presented at the ESC congress.
The series is aimed to explore the background and practical implications of recent scientific developments, like those discussed in the Rapid Fire session on What's new in hereditary dyslipidaemia at the ESC Congress 2016, with speakers in this session.
Faculty & Disclosures
Kausik Ray - Professor of Public Health in the Department of Public Health and Primary Care at Imperial College London, Honorary Consultant Cardiologist at the Imperial College NHS Trust, United Kingdom
Johanneke van den Berg and Corien Flint - UMC Utrecht, The Netherlands
The speakers did not receive financial compensation for participating in these interviews.